Halozyme Therapeutics (HALO) Change in Cash (2010 - 2026)
Halozyme Therapeutics (HALO) reported Change in Cash of $175.6 million for Q1 2026, up 190.33% year-over-year from $60.5 million in Q1 2025, and up 161.99% quarter-over-quarter from -$283.2 million in Q4 2025.
Halozyme Therapeutics (HALO) Change in Cash (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 17 years of Change in Cash data on file, last reported at $175.6 million in Q1 2026.
- Change in Cash for Q1 2026 came in at $175.6 million, up 190.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $135.7 million (up 1059.57% YoY), and the FY2025 annual result was $20.6 million, up 916.31% from the prior year.
- Change in Cash improved to $175.6 million in Q1 2026 per HALO's latest filing, from -$283.2 million in the prior quarter.
- Over five years, Change in Cash peaked at $357.8 million in Q3 2025 and troughed at -$283.2 million in Q4 2025.
- A 5-year average of $11.3 million and a median of $23.2 million in 2024 frame the typical range for Change in Cash.
- The sharpest annual moves came in 2023 and 2025: Change in Cash slumped 15489.59% in 2023, then jumped 1166.61% in 2025.
- A 5-year view of Change in Cash shows it stood at $87.0 million in 2022, then sank by 279.07% to -$155.9 million in 2023, then jumped by 75.32% to -$38.5 million in 2024, then plunged by 636.31% to -$283.2 million in 2025, then jumped by 161.99% to $175.6 million in 2026.
- Business Quant data shows HALO's Change in Cash at $175.6 million in Q1 2026, -$283.2 million in Q4 2025, and $357.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 623.00 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 417.10 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -45.97 Mn |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 175.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 175.59 Mn |
| Dec 31, 2025 | -283.24 Mn |
| Sep 30, 2025 | 357.80 Mn |
| Jun 30, 2025 | -114.47 Mn |
| Mar 31, 2025 | 60.48 Mn |
| Dec 31, 2024 | -38.47 Mn |
| Sep 30, 2024 | -33.55 Mn |
| Jun 30, 2024 | 23.24 Mn |
| Mar 31, 2024 | 46.26 Mn |
| Dec 31, 2023 | -155.86 Mn |
| Sep 30, 2023 | 53.06 Mn |
| Jun 30, 2023 | 124.28 Mn |
| Mar 31, 2023 | -137.81 Mn |
| Dec 31, 2022 | 87.04 Mn |
| Sep 30, 2022 | 56.23 Mn |
| Jun 30, 2022 | -26.90 Mn |
| Mar 31, 2022 | -884,000.00 |
| Dec 31, 2021 | -372.96 Mn |
| Sep 30, 2021 | 44.72 Mn |
| Jun 30, 2021 | -52.48 Mn |